DB:1FG

Stock Analysis Report

Executive Summary

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has FibroGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1FG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

21.1%

1FG

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-38.0%

1FG

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 1FG underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 1FG underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

1FGIndustryMarket
7 Day21.1%11.2%7.3%
30 Day-17.4%-5.3%-17.9%
90 Day-25.2%-21.9%-25.8%
1 Year-38.0%-38.0%-4.9%-5.1%-15.1%-17.7%
3 Year31.9%31.9%17.7%16.5%-18.7%-25.6%
5 Year6.2%6.2%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is FibroGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is FibroGen undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1FG (€29.92) is trading below our estimate of fair value (€242.02)

Significantly Below Fair Value: 1FG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1FG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1FG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1FG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1FG is overvalued based on its PB Ratio (5.7x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is FibroGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

54.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1FG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1FG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1FG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1FG's revenue (20.2% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 1FG's revenue (20.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1FG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has FibroGen performed over the past 5 years?

7.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1FG is currently unprofitable.

Growing Profit Margin: 1FG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1FG is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare 1FG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1FG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 1FG has a negative Return on Equity (-14.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is FibroGen's financial position?


Financial Position Analysis

Short Term Liabilities: 1FG's short term assets ($702.5M) exceed its short term liabilities ($102.7M).

Long Term Liabilities: 1FG's short term assets ($702.5M) exceed its long term liabilities ($219.2M).


Debt to Equity History and Analysis

Debt Level: 1FG's debt to equity ratio (3.1%) is considered satisfactory.

Reducing Debt: 1FG's debt to equity ratio has reduced from 6.7% to 3.1% over the past 5 years.


Balance Sheet

Inventory Level: 1FG has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1FG's debt is covered by short term assets (assets are 41.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1FG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1FG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is FibroGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1FG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1FG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1FG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1FG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1FG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Enrique Conterno (52yo)

0.17

Tenure

Mr. Enrique A. Conterno is the Chief Executive Officer and Director at FibroGen, Inc. since January 6, 2020. He served as President of Lilly USA from January 2017 to 2019. Mr. Conterno served as President  ...


Leadership Team

NamePositionTenureCompensationOwnership
James Schoeneck
Chairman of the Board0.17yrUS$475.88k0.068% $1.8m
Pat Cotroneo
Senior VP of Finance & CFO12.17yrsUS$3.57m0.22% $5.7m
K. Yu
Chief Medical Officer3.92yrsUS$4.53m0.13% $3.5m
Enrique Conterno
CEO & Director0.17yrno datano data
Barry Berkowitz
25.17yrsno datano data
Michael Martinelli
Senior Vice President of Technical Development8.5yrsno datano data
Karen Bergman
Vice President of Investor Relations & Corporate Communications3.5yrsno datano data
Michael Lowenstein
Chief Legal Officer3.92yrsno datano data
Richard Farley
Vice President of Human Resources4.5yrsno datano data
Leanne Price
Chief Intellectual Property Officer3.92yrsno datano data

3.9yrs

Average Tenure

57yo

Average Age

Experienced Management: 1FG's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Schoeneck
Chairman of the Board0.17yrUS$475.88k0.068% $1.8m
Enrique Conterno
CEO & Director0.17yrno datano data
Rory Riggs
Independent Director26.42yrsUS$462.57k0.43% $11.5m
Jeffrey Henderson
Independent Director4.58yrsUS$455.07k0.0042% $111.6k
Roberto Rosenkranz
Independent Director9.92yrsUS$455.07k0.071% $1.9m
Thomas Kearns
Lead Independent Director2.75yrsUS$488.38k0.28% $7.5m
Kalevi Kurkijärvi
Independent Director23.33yrsUS$460.07k0.027% $715.4k
George Martin
Chairman of Scientific Advisory Boardno datano datano data
Jeffrey Edwards
Independent Director4.42yrsUS$470.07k0.0042% $111.6k
Toshinari Tamura
Independent Director11.5yrsUS$455.07k0.059% $1.6m

4.6yrs

Average Tenure

66yo

Average Age

Experienced Board: 1FG's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Company Information

FibroGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: FibroGen, Inc.
  • Ticker: 1FG
  • Exchange: DB
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.945b
  • Listing Market Cap: US$2.656b
  • Shares outstanding: 88.00m
  • Website: https://www.fibrogen.com

Number of Employees


Location

  • FibroGen, Inc.
  • 409 Illinois Street
  • San Francisco
  • California
  • 94158
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FGENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2014
1FGDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014
FGEN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2014
0IL8LSE (London Stock Exchange)YesCommon StockGBUSDNov 2014
1FGBRSE (Berne Stock Exchange)YesCommon StockCHCHFNov 2014

Biography

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:37
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.